FDA proposal to curb cheap copycats boosts Novo Nordisk shares 4.8%, but pricing pressure, competition, and a grim 2026 forecast keep the stock near 52-week lows.<\/p>\n
A surprise regulatory proposal out of Washington has handed Novo Nordisk a rare moment of relief, but the Danish drugmaker\u2019s longer-term picture remains clouded by pricing pressure, intensifying competition, and a grim 2026 forecast.<\/p>\n
FDA Proposal Could Curb Cheap Copycats<\/p>\n
The US Food and Drug Administration has put forward a plan to remove several active ingredients \u2014 including semaglutide, tirzepatide, and liraglutide \u2014 from its 503B bulk substances list. That list currently allows compounding pharmacies to produce cheaper, custom-made versions of branded drugs. Semaglutide is the engine behind Novo Nordisk\u2019s blockbuster obesity and diabetes treatments Ozempic and Wegovy.<\/p>\n
The agency argues there is no clinical need for such compounding, a move that, if finalized, would eliminate a key source of price competition. Compounded versions are often sold at a steep discount to the originals.<\/p>\n
The market wasted no time reacting. Novo Nordisk shares climbed roughly 4.8% on Thursday to \u20ac36.20, making it the strongest performer on the Copenhagen exchange and hitting its highest level in more than two months.<\/p>\n
Should investors sell immediately? Or is it worth buying Novo Nordisk?<\/a><\/p>\n But the Bigger Picture Is Bleak<\/p>\n That rally, however, needs context. The stock is still down nearly 19% year-to-date and roughly 38% over the past 12 months. The 52-week high of \u20ac70.13 \u2014 set in June 2025 \u2014 remains a distant memory.<\/p>\n The structural headwinds are formidable. Novo Nordisk expects revenue and operating profit to fall by 5% to 13% in 2026, measured at constant exchange rates. The primary culprit: declining net prices in the US, where Medicare Part D negotiations and most-favored-nation clauses are squeezing margins.<\/p>\n Competition is also heating up. Eli Lilly secured FDA approval for Foundayo, an oral GLP-1 drug, in early April. While early sales data have been mixed, the mere presence of another player in the oral GLP-1 space adds pressure on Novo Nordisk\u2019s own pipeline. A market once dominated by two players is growing increasingly crowded.<\/p>\n Analyst Sentiment Sours<\/p>\n The shifting landscape has rattled Wall Street. The average price target for Novo Nordisk has been cut by more than 21% over the past three months, and the consensus rating now sits at \u201cHold.\u201d Several institutional investors have trimmed their positions, signaling waning patience for a quick turnaround.<\/p>\n On the technical side, the relative strength index has dipped to around 25, a level that typically suggests oversold conditions. Whether that signals a bottom or simply reflects the depth of the selloff will likely become clearer when first-quarter results are released in early May.<\/p>\n